Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY.
Am J Ther. 2023;30(4):e347-e352. doi: 10.1097/MJT.0000000000001643.
Obesity is a major and growing public health concern. The associated cost for obesity and its related comorbidities is approximately 30% of US health care expenditures annually. As additional pharmacotherapeutic options join the market to combat obesity, it is important to understand the financial impact it may have on overall health care costs. This article explores the efficacy and pharmacoeconomics of incretin mimetics, semaglutide and tirzepatide, in the setting of obesity.
The cost of incretin mimetics (semaglutide and tirzepatide) and its overall impact on obesity management within the health care arena is being explored. The cost comparison of these medications is to be determined; however, it may represent an added cost to the total US health care expenditures.
A PubMed and Google Scholar search was conducted using various search terms (eg, semaglutide, tirzepatide, pharmacoeconomics, and obesity).
Based on the data reviewed, both semaglutide and tirzepatide are effective medication options for obesity management. Obesity-related management expenditures exceed $173 billion for the US health care system annually. The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide was reported as $1845 and $985, respectively. More than 40% of adults (60 years or older) experience obesity. If 1%, 5%, or 10% of this population is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively. Tirzepatide is not yet approved in the United States for obesity and its financial impact remains to be seen.
Obesity is associated with burdensome health complications and costs. Semaglutide and tirzepatide are effective drug options for the management of obesity. The cost of these medications will no doubt present a challenge to the total health care expenditures, although the cost-benefit ratio may ultimately be favorable.
肥胖是一个主要且日益严重的公共卫生问题。肥胖及其相关并发症每年造成的医疗费用约占美国医疗保健支出的 30%。随着更多的减肥药物加入市场以对抗肥胖，了解其对整体医疗保健成本的可能影响非常重要。本文探讨了肠促胰岛素类似物（司美格鲁肽和替西帕肽）在肥胖治疗中的疗效和药物经济学。
正在探索肠促胰岛素类似物（司美格鲁肽和替西帕肽）的成本及其在医疗保健领域对肥胖管理的整体影响。这些药物的成本比较尚待确定，但它可能会增加美国医疗保健总支出。
通过各种搜索词（如司美格鲁肽、替西帕肽、药物经济学和肥胖）在 PubMed 和谷歌学术上进行了搜索。
根据审查的数据，司美格鲁肽和替西帕肽都是肥胖管理的有效药物选择。美国医疗保健系统每年因肥胖相关管理支出超过 1730 亿美元。报道称，司美格鲁肽和替西帕肽治疗体重减轻 1%的成本分别为 1845 美元和 985 美元。超过 40%的成年人（60 岁或以上）患有肥胖症。如果这一人群的 1%、5%或 10%接受司美格鲁肽治疗，每年的医疗保险费用将分别超过 26.8 亿美元、133 亿美元和 268 亿美元。替西帕肽尚未在美国获得肥胖症的批准，其经济影响尚待观察。
肥胖与严重的健康并发症和费用有关。司美格鲁肽和替西帕肽是肥胖管理的有效药物选择。这些药物的成本无疑将对总医疗保健支出构成挑战，尽管成本效益比最终可能是有利的。
